drugset / Trial / NCT06196827
Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety, tolerability and efficacy of LX101 in subjects with biallelic RPE65 mutation-associated inherited retinal dystrophy.
Timeline
- Start
- 2022-07-02
- Primary completion
- 2023-12-06
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LX101 | Gene therapy (AAV / viral vector) | — | Other |